
发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
:Increasing evidence suggests a role for the ET (endothelin) system in preeclampsia. Hence, blocking this system with endothelin receptor antagonists (ERAs) could be a therapeutic strategy. Yet, clinical studies are lacking due to possible teratogenic effects of ERAs. In this study, we investigated the placental transfer of ERAs and their effect on ET-1-mediated vasoconstriction. Term placentas were dually perfused with the selective ETAR (ET type A receptor) antagonists sitaxentan and ambrisentan or the nonselective ETAR/ETBR antagonist macitentan and subsequently exposed to ET-1 in the fetal circulation. ET-1 concentration-response curves after incubation with sitaxentan, ambrisentan, macitentan, or the selective ETBR antagonist BQ-788 were also constructed in isolated chorionic plate arteries using wire-myography, and gene expression of the ET-system was quantified in healthy and early onset preeclamptic placentas. At steady state, the mean fetal-to-maternal transfer ratios were 0.32±0.05 for sitaxentan, 0.21±0.02 for ambrisentan, and 0.05±0.01 for macitentan. Except for BQ-788, all ERAs lowered the response to ET-1, both in the perfused cotyledon and isolated chorionic plate arteries. Placental gene expression of ECE-1, ETAR, and ETBR were comparable in healthy and preeclamptic placentas, while ET-1 expression was higher in preeclampsia. Our study is the first to show direct transfer of ERAs across the term human placenta. Furthermore, ETAR exclusively mediates ET-1-induced constriction in the fetoplacental vasculature. Given its limited transfer, macitentan could be considered as potential preeclampsia therapy. Extending knowledge on placental transfer to placentas of preeclamptic pregnancies is required to determine whether ERAs might be applied safely in preeclampsia.
展开更多
最新影响因子:9.897 | 期刊ISSN:0194-911X | CiteScore:5.34 |
出版周期:Monthly | 是否OA:YES | 出版年份:1979 |
期刊官方网址:http://hyper.ahajournals.org/
期刊投稿地址:http://hype-submit.aha-journals.org/cgi-bin/main.plex
自引率:9.70% | 研究方向:医学-外周血管病 |
出版地区:UNITED STATES |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
This journal provides a forum for the presentation of scientific investigation of the highest quality in the broad field of blood pressure regulation and the pathophysiological mechanisms underlying hypertensive diseases.
这本杂志提供了一个论坛,介绍了在广泛的血压调节领域中最高质量的科学研究和高血压疾病的病理生理机制。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
PERIPHERAL VASCULAR DISEASE(周围血管疾病) 1区 |
3/65 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
271 | 254 | 17 |
引文计数(2018)
文献(2015-2017)
6818次引用
1276篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Internal Medicine
|
#6/121
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
14年经验沉淀,实体公司
运营
liting7111
研究方向:医药科学 循环系统 血压调节异常 高血压病
审稿时间: 2个月内
liting7111
研究方向:高血压
接受率: 比较困难(25%命中)
liting7111
接受率: 比较困难(25%命中)
liting7111
研究方向:高血压
接受率: 比较困难(25%命中)
liting7111
liting7111
研究方向:高血压 认知功能
接受率: 比较困难(25%命中)
liting7111
研究方向:高血压 心脏 心血管
接受率: 中等(50%命中)
影响因子:3.413
ISSN:1546-0096
研究方向:PEDIATRICS-RHEUMATOLOGY
影响因子:2.858
ISSN:0961-2033
研究方向:医学-风湿病学
影响因子:7.046
ISSN:1462-0324
研究方向:医学-风湿病学
影响因子:5.263
ISSN:1297-319X
研究方向:医学-风湿病学
影响因子:2.862
ISSN:1439-7595
研究方向:RHEUMATOLOGY-
影响因子:3.65
ISSN:0770-3198
研究方向:医学-风湿病学
影响因子:0.159
ISSN:0341-051X
研究方向:医学-风湿病学
影响因子:5.346
ISSN:0315-162X
研究方向:医学-风湿病学
影响因子:15.483
ISSN:2326-5191
研究方向:RHEUMATOLOGY-
HYPERTENSION 投稿经验
(由下方点评分析获得,7人参与,25151人阅读)